Search

everythinglearnresearchcommunity

for

Search:↓

A protein called EGFR protects hair follicle stem cells, and when it's disrupted, hair follicles can be damaged, but blocking certain pathways can restore hair growth.

A teenager had both alopecia areata and vitiligo, which are rare to occur together.

Alopecia areata is a hair loss condition caused by immune factors and can be treated with JAK inhibitors.

Finasteride can cause a unique skin reaction on the penile shaft.

Natural killer and CD8+ T cells play a key role in hair loss in androgenetic alopecia.

Serum granulysin levels can indicate the activity and prognosis of alopecia areata.

The patient's symptoms improved with treatment but recurred when the steroid dose was reduced, requiring ongoing therapy.

Postmenopausal women may experience frontal hairline and eyebrow loss due to cicatricial fibrosis.

Alopecia areata patients have fewer protective regulatory B cells, which may contribute to the disease.

IL-17 is more important than IFN-γ in causing severe hair loss in chronic alopecia areata.

Tissue environment greatly affects the unique epigenetic makeup of regulatory T cells, which could impact autoimmune disease treatment.

Non-immune dermal cells dominate, epidermal cells increase after day 9, and certain immune cells persist beyond inflammation in wound-induced hair follicle regeneration.

Alopecia areata patients have more activated T cells in their blood, which may help in developing treatments.

Alopecia areata in children is caused by the immune system attacking hair follicles due to genetic factors.

Sintilimab treatment caused hair loss but led to complete tumor remission.

Patients with RASopathies are at risk for autoimmune disorders and should be routinely screened.

T cells affect skin cell genes in inflammatory diseases, and therapy can normalize these changes.

Blocking JAK3 signaling can reverse hair loss from alopecia areata.

The model helps understand and improve treatments for alopecia areata by simulating hair growth and immune cell interactions.

A new mouse model for vitiligo helps study immune responses and potential treatments.

New targeted immunotherapies are improving treatment for inflammatory skin diseases.

Alopecia areata may be treated by restoring hair follicle immune privilege and adjusting immune responses.

Stress may contribute to hair loss in alopecia areata by affecting immune responses and cell death in hair follicles.

RIPK1 inhibitors may help prevent alopecia areata by reducing immune cell activity.

Canine pemphigus foliaceus involves significant immune activity and shares similarities with human pemphigus.

Different types of hair loss have unique cellular changes, suggesting new treatment targets.

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

Thymus transplantation successfully restored immune function in infants with FOXN1 deficiency.

2-deoxy D-glucose does not help with hair regrowth in alopecia areata.

Vitiligo and alopecia areata may have similar causes despite their differences.